Form 4: Nuo Therapeutics Insider Trades Common Stock

Scott M. Pittman, a Director and 10% Owner of Nuo Therapeutics, Inc., reported transactions involving the acquisition and net exercise of stock options.

Summary

• Scott M. Pittman, a Director and 10% Owner of Nuo Therapeutics, Inc., engaged in several transactions on June 29th and June 30th, 2026.
• Pittman acquired 40,000 shares of common stock at a price of $1.00 per share.
• Additionally, Pittman executed a net exercise of stock options, resulting in the acquisition of 39,604 shares of common stock at a price of $1.01 per share. This transaction involved the withholding of 39,604 shares to cover the exercise price, based on a closing price of $1.01.
• Following these transactions, Pittman beneficially owns 5,400,396 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While insider transactions can signal confidence, the net exercise of options involves realizing gains and potentially selling shares, which is a common financial planning activity for executives and does not necessarily indicate a strong positive or negative outlook for the company itself.

Positives

• Scott M. Pittman, a key insider (Director and 10% Owner), increased his beneficial ownership of Nuo Therapeutics' common stock.
• The acquisition of 40,000 shares at $1.00 and the net exercise of options for 39,604 shares at $1.01 suggest continued investment and confidence in the company.
• The net exercise of options indicates that the stock price is above the exercise price, a positive sign for the value of outstanding options.

Negatives

• The net exercise of options resulted in the withholding of a significant number of shares (39,604) to cover the exercise price and associated costs, reducing the net shares received by the reporting person.
• The filing does not provide details on the overall financial health or performance of Nuo Therapeutics, Inc., only insider transactions.

Risks

• The filing does not explicitly mention any risks. However, the transactions are subject to market risks associated with the stock price of Nuo Therapeutics, Inc.
• The net exercise of options implies that the reporting person is realizing gains, which could be influenced by future stock performance and market volatility.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports on past transactions by an insider.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reported transactions by Scott M. Pittman, a Director and 10% Owner, indicate personal investment activity within Nuo Therapeutics, Inc. Such filings are crucial for investors to understand insider sentiment and potential alignment of interests.

Stakeholder Impact

• Shareholders: The transactions may provide some insight into insider confidence, but the direct impact on share price is likely minimal without broader company news.
• Employees: The net exercise of options by management could indirectly affect employee morale depending on the company's overall performance and stock option plans.
• Creditors: No direct impact is indicated by this filing.
• Suppliers: No direct impact is indicated by this filing.
• Customers: No direct impact is indicated by this filing.

Next Steps

• Continued monitoring of insider transactions for Nuo Therapeutics, Inc. to gauge management's ongoing conviction.
• Further analysis of Nuo Therapeutics, Inc.'s financial reports and strategic updates to understand the underlying business performance.

Key Dates

Keywords

Nuo Therapeutics, AURX, Form 4, Insider Trading, Stock Options, Common Stock, Beneficial Ownership, Scott M. Pittman, SEC Filing, Securities Exchange Act